Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.70 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.65 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.65 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.64 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142169 | 1.00 | ITGAV (0.70) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL29797176 | 1.00 | ITGAV (0.70) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20142541 | 1.00 | ITGAV (0.70) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20139777 | 0.93 | ITGAV (0.62) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL30850808 | 0.87 | ITGAV (0.64) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20141952 | 0.87 | ITGAV (0.64) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20141955 | 0.87 | ITGAV (0.64) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL21294646 | 0.87 | ITGAV (0.64) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL21294592 | 0.85 | ITGAV (0.70) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL20153370 | 0.84 | ITGAV (0.69) | ITGAVITGB3ITGB1ITGA5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | claimed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | ITGAV 1/4885ITGB3 2/4885ITGB1 3/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGAV 3/4885ITGB3 1/4885ITGB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.